Disseminated Intravascular Coagulation

Disseminated Intravascular Coagulation (DIC) is a life-threatening acquired disorder characterized by the systemic activation of coagulation, leading to the formation of widespread microthrombi in small blood vessels. This paradoxically results in both excessive clotting and subsequent depletion of coagulation factors and platelets, leading to a bleeding diathesis. It is not a primary disease but a complication of an underlying condition.

DIC is triggered by severe underlying conditions that provoke widespread activation of the coagulation cascade. Common precipitating events include sepsis (especially gram-negative bacteria), massive trauma, severe burns, certain malignancies (e.g., acute promyelocytic leukemia, adenocarcinoma), obstetric complications (e.g., placental abruption, amniotic fluid embolism), and extensive tissue damage.

The core mechanism of DIC involves the release of procoagulant substances into the circulation. This can be initiated by tissue factor exposure from damaged endothelium or malignant cells, or by endotoxins from bacteria. These substances activate the coagulation cascade, leading to the generation of thrombin and subsequent fibrin deposition. The formation of microthrombi consumes platelets and coagulation factors (fibrinogen, prothrombin, factors V, VIII, XIII), leading to their depletion. Simultaneously, the fibrinolytic system is activated to break down these clots, producing fibrin degradation products (FDPs) and D-dimers, which further impair coagulation and contribute to bleeding. This vicious cycle of thrombosis and hemorrhage can lead to widespread organ damage.

The incidence of DIC varies widely depending on the underlying condition and healthcare setting. It is more common in critically ill patients, particularly in intensive care units (ICUs). Sepsis is the most frequent cause, accounting for approximately 50% of DIC cases. Malignancy and trauma are also significant contributors. There is no strong predilection for age or gender, though it can occur at any age.

• Sepsis
• Severe trauma or injury
• Extensive burns
• Malignancy (especially leukemias and solid tumors)
• Obstetric complications
• Transfusion reactions
• Snake bites
• Heat stroke
• Aortic aneurysm rupture
• Vasculitis

A. Early Symptoms

• Petechiae (small red or purple spots on the skin)


• Purpura (larger purple areas due to bleeding under the skin)


• Ecchymoses (bruises) B. Common Symptoms


• Bleeding from venipuncture sites


• Mucosal bleeding (gums, nosebleeds)


• Hematuria (blood in urine)


• Melena or hematochezia (blood in stool)


• Unexplained bruising C. Advanced Symptoms


• Organ dysfunction due to microthrombi (e.g., renal failure, respiratory distress, neurological changes)


• Hypotension


• Tachycardia


• Shock D. Emergency Symptoms


• Profuse, uncontrolled bleeding


• Altered mental status, confusion, coma


• Seizures


• Severe shortness of breath or respiratory failure


• Hemorrhage into vital organs (brain, lungs)

• Vital signs: Tachycardia, hypotension, tachypnea, fever (if sepsis-related), hypothermia.
• Inspection: Widespread petechiae, purpura, ecchymoses, oozing from surgical sites or existing wounds, pallor, jaundice (if associated with liver disease or hemolysis).
• Palpation: May reveal enlarged liver or spleen.
• Auscultation: May reveal murmurs indicative of anemia or cardiac dysfunction.

A. Clinical Assessment
Detailed history focusing on underlying conditions, recent illnesses, trauma, medications, and symptoms of bleeding or organ dysfunction. B. Laboratory Testing
Key laboratory tests are crucial for diagnosis and monitoring. C. Imaging Studies
Used to identify the underlying cause or assess for complications such as organ infarction or bleeding. D. Functional Tests
Evaluation of clotting times and platelet function. E. Biopsy Findings
Rarely indicated, but may show microthrombi in affected tissues. F. Genetic Testing
Not typically used in the acute diagnosis of DIC, but may be relevant in inherited thrombophilias that can predispose to DIC in certain contexts. G. Differential Diagnosis
Must be differentiated from other bleeding disorders, thrombotic disorders, and conditions causing multiorgan dysfunction.

Test Name: Platelet Count
Type: Blood Test
Purpose: To assess the number of platelets available for clotting.
Expected Findings: Thrombocytopenia (low platelet count) is characteristic of DIC.
Interpretation: A significant drop in platelets or a count below 100,000/µL is concerning. Test Name: Prothrombin Time (PT)
Type: Blood Test
Purpose: Measures the extrinsic and common pathways of coagulation.
Expected Findings: Prolonged PT.
Interpretation: Indicates depletion of factors in these pathways. Test Name: Activated Partial Thromboplastin Time (aPTT)
Type: Blood Test
Purpose: Measures the intrinsic and common pathways of coagulation.
Expected Findings: Prolonged aPTT.
Interpretation: Indicates depletion of factors in these pathways. Test Name: Fibrinogen Level
Type: Blood Test
Purpose: Assesses the level of this key clotting protein.
Expected Findings: Low fibrinogen levels.
Interpretation: Consistent with consumption of clotting factors. Test Name: D-dimer
Type: Blood Test
Purpose: Detects the presence of fibrin degradation products.
Expected Findings: Elevated D-dimer levels.
Interpretation: Indicates active fibrinolysis, a hallmark of DIC. Test Name: Fibrin Degradation Products (FDPs)
Type: Blood Test
Purpose: Detects products of fibrinolysis.
Expected Findings: Elevated FDPs.
Interpretation: Similar to D-dimer, indicates active clot breakdown.

• Chest X-ray: Purpose: To assess for pulmonary complications like ARDS or bleeding. Typical Findings: May show infiltrates, effusions, or signs of pulmonary edema. Clinical Importance: Helps evaluate respiratory compromise.
• Abdominal Ultrasound/CT: Purpose: To identify underlying causes like trauma, malignancy, or aortic dissection, and assess for organ damage or bleeding. Typical Findings: Varies based on the underlying cause; may show organ infarction or hemorrhage. Clinical Importance: Crucial for identifying precipitating factors and complications.
• CT Scan of the Brain: Purpose: To assess for intracranial hemorrhage. Typical Findings: May reveal evidence of bleeding. Clinical Importance: Essential in patients with neurological symptoms.

• Liver Disease: Can cause coagulopathy due to reduced synthesis of clotting factors, but typically has normal platelet counts and different coagulation profiles.
• Severe Hemophilia/Von Willebrand Disease: Inherited bleeding disorders, usually present earlier in life and with a history of bleeding.
• Thrombotic Thrombocytopenic Purpura (TTP)/Hemolytic Uremic Syndrome (HUS): Characterized by thrombocytopenia, microangiopathic hemolytic anemia, and neurological symptoms (TTP) or renal failure (HUS). Lacks the widespread activation of coagulation seen in DIC.
• Anticoagulant Overdose: Can cause bleeding but without the characteristic laboratory findings of DIC.

• Hemorrhage: Severe and uncontrolled bleeding, potentially leading to hypovolemic shock and death.
• Organ Infarction: Due to widespread microthrombi, leading to ischemia and damage of organs like kidneys, lungs, brain, and gastrointestinal tract.
• Renal Failure: Acute kidney injury due to microvascular thrombosis and hypoperfusion.
• Respiratory Failure: Acute Respiratory Distress Syndrome (ARDS) or pulmonary hemorrhage.
• Neurological Deficits: Stroke, seizures, or coma due to cerebral microthrombi or hemorrhage.
• Limb Ischemia: Gangrene in extremities due to vascular occlusion.
• Adrenal Hemorrhage: Can lead to adrenal insufficiency.

A. Lifestyle Modifications
Not applicable in the acute setting. Focus is on managing the underlying condition. B. Preventive Measures
Early identification and management of conditions that predispose to DIC. C. Medical Treatment
| Drug Class | Mechanism of Action | Examples |
| :-------------------------- | :-------------------------------------------------------------------------------------------------------------------------- | :--------------------------------------------------------------------------- |
| Replacement Therapy | Replaces consumed clotting factors and platelets to correct coagulopathy and control bleeding. | Fresh Frozen Plasma (FFP), Cryoprecipitate, Platelet Concentrates, Packed Red Blood Cells |
| Anticoagulants (Limited)| Used cautiously in specific situations (e.g., predominant thrombosis with minimal bleeding) to inhibit further clot formation. | Heparin |
| Recombinant Activated Protein C (Drotrecogin alfa) | Inhibits coagulation and inflammation. Use is now limited due to mixed results in trials. | Drotrecogin alfa (Xigris) - largely withdrawn from market in many regions. |
| Underlying Cause Treatment| Critical for resolving DIC. | Antibiotics (sepsis), chemotherapy (malignancy), surgery (trauma/obstetric) | D. Surgical Treatment
Surgery may be required to control the source of bleeding or remove necrotic tissue, or to manage the underlying cause (e.g., evacuation of hematoma, removal of infected tissue). E. Interventional Procedures
Angioembolization may be used to control specific sites of hemorrhage. F. Rehabilitation
Focuses on managing sequelae of organ damage, physical therapy for weakness, and psychological support. G. Emergency Management
Immediate management of shock, aggressive fluid resuscitation, and blood product transfusion to control hemorrhage.

The prognosis of DIC is highly variable and depends on the underlying cause, the severity of the disease, and the promptness and effectiveness of treatment. Mortality rates can range from 20% to over 80%. Early diagnosis and aggressive management of the underlying condition are critical for improving outcomes. Survivors may experience long-term complications related to organ damage.

Primary prevention involves prompt and effective treatment of underlying conditions that predispose to DIC, such as sepsis, trauma, and obstetric emergencies. Secondary prevention involves close monitoring of at-risk patients for early signs of DIC. There is no general screening for DIC in the absence of symptoms or a known precipitating event.

The following homeopathic remedies have been historically indicated for symptoms associated with Disseminated Intravascular Coagulation. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Disseminated Intravascular Coagulation.